saRNA LNPs induce high, Th-1 biased antibodies against SARS-CoV-2 in Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice
Mouse serum was found to have high quantities of SARS-CoV-2 specific IgG after 6 weeks. Mice infected with 10 and 1 μg of saRNA LNP had statistically significantly higher quantities of IgG response compared to mice that received 10 μg of electroplated pDNA. All mice that received saRNA LNP vaccine had higher quantities of SARS-CoV-2 specific IgG response compared to patients who recovered from COVID-19. Both the pDNA and saRNA LNP immunizations were able to induce Th1-biased response in mice.
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
saRNA LNPs induce neutralization of pseudo- and wild-type SARS-CoV-2 in Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice
saRNA LNPs induce high, Th-1 biased antibodies against SARS-CoV-2 in Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice
SARS-CoV-2 IgG correlates directly with viral neutralization in Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice
Cellular and cytokine responses to saRNA LNP SARS-CoV-2 vaccine in Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice
Learn After
Fig. 1: Antibody quantification and neutralization of a SARS-CoV-2 saRNA vaccinated mice compared to COVID-19 recovered patients in Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice
Fig. 2: Th1/Th2 skew in response to SARS-CoV-2 saRNA LNP vaccine in Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice